Gastroenterology
Volume 130, Issue 1 , Pages 231-264 , January 2006

American Gastroenterological Association Technical Review on the Management of Hepatitis C

  • Jules L. Dienstag

      Affiliations

    • Gastrointestinal Unit (Medical Services) Massachusetts General Hospital Department of Medicine and Office of the Dean for Medical Education Harvard Medical School Boston, Massachusetts
    • Corresponding Author InformationAddress requests for reprints to: Chair, Clinical Practice and Economics Committee, AGA National Office, c/o Membership Department, 4930 Del Ray Avenue, Bethesda, Maryland 20814Fax: (301) 654-5920.
    • ,
  • John G. McHutchison

      Affiliations

    • Duke Clinical Research Institute Division of Gastroenterology Duke University Medical Center Durham, North Carolina

References 

  1. Lauer GM , Walker BD . Hepatitis C virus infection . N Engl J Med . 2001;345:41–52
  2. Alter MJ , Mast EE . The epidemiology of viral hepatitis in the United States . Gastroenterol Clin North Am . 1994;23:437–455
  3. World Health Organization . Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium . J Viral Hepat . 1999;6:35–47
  4. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, et al. Prevalence of chronic liver disease in the general population of northern Italy (the Dionysos study) . Hepatology . 1994;20:1442–1449
  5. Kim WR , Gross JB , Poterucha JJ , Locke GR , Dickson ER . Outcome of hospital care of liver disease associated with hepatitis C in the United States . Hepatology . 2001;33:201–206
  6. Detre KM , Belle SH , Lombardero M . Liver transplantation for chronic viral hepatitis . Viral Hepat Rev . 1997;2:219–228
  7. Féray C, Gigou M, Sameul D, Paradis V, Wilber J, David MF, et al. The course of hepatitis C virus infection after liver transplantation . Hepatology . 1994;20:1137–1143
  8. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 . N Engl J Med . 1999;341:556–562
  9. Wong JB , McQuillan GM , McHutchison JG , Poynard T . Estimating future hepatitis C morbidity, mortality, and costs in the United States . Am J Public Health . 2000;90:1562–1569
  10. Kim WR . The burden of hepatitis C in the United States . Hepatology . 2002;36(Suppl 1):S30–S34
  11. Kim WR , Brown RS , Terrault NA , El-Serag H . Burden of liver disease in the United States (summary of a workshop) . Hepatology . 2002;36:227–242
  12. Davis GL , Albright JE , Cook SE , Rosenberg D . Projecting future complications of chronic hepatitis C in the United States . Liver Transpl . 2003;9:331–338
  13. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo Q-L, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis . N Engl J Med . 1989;321:1494–1500
  14. Donahue JG, Munoz A, Ness PM, Brown DEJ, Yawn DH, McAllister HAJ, et al. The declining risk of post-transfusion hepatitis C virus infection . N Engl J Med . 1992;327:369–373
  15. Schreiber GB , Busch MP , Kleinman SH , Korelitz JJ . The risk of transfusion-transmitted viral infection . N Engl J Med . 1996;334:1685–1690
  16. Aach RD, Stevens CE, Hollinger FB, Mosley JW, Peterson DA, Taylor PE, et al. Hepatitis C virus infection in post-transfusion hepatitis (an analysis with first- and second-generation assays) . N Engl J Med . 1991;325:1325–1329
  17. Williams I . Epidemiology of hepatitis C in the United States . Am J Med . 1999;107:2S–9S
  18. Orland JR , Wright TL , Cooper S . Acute hepatitis C . Hepatology . 2001;33:321–327
  19. Stramer SL, Glynn SA, Kleinman SH, Strong M, Caglioti S, Wright DJ, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing . N Engl J Med . 2004;351:760–768
  20. Armstrong GL , Alter MJ , McQuillan GM , Margolis HS . The past incidence of hepatitis C virus infection (implications for the future burden of chronic liver disease in the United States) . Hepatology . 2000;31:777–782
  21. Buti M, San Miguel R, Brosa M, Cabasés JM, Medina M, Casado MA, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C . J Hepatol . 2005;42:639–645
  22. American Gastroenterological Association . Position and policy statement (policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers) . Gastroenterology . 1995;108:925–926
  23. Centers for Disease Control and Prevention . Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease . MMWR Morb Mortal Wkly Rep . 1998;47:1–39
  24. National Institutes of Health Consensus Development Conference . Management of hepatitis C . Hepatology . 1997;26(Suppl 1):1S–156S
  25. Consensus statement. EASL International Consensus Conference on Hepatitis C . J Hepatol . 1999;30:956–961
  26. National Institutes of Health Consensus Development Conference statement . management of hepatitis C (2002—June 10–12, 2002) . Hepatology . 2002;36(Suppl 1):S3–S20
  27. U.S. Preventive Services Task Force . Screening for hepatitis C virus infection in adults (recommendation statement) . Ann Intern Med . 2004;140:462–464
  28. Chou R , Clark EC , Helfand M . Screening for hepatitis C virus infection (a review of the evidence for the U.S. Preventive Services Task Force) . Ann Intern Med . 2004;140:465–479
  29. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection . Hepatology . 2001;34:809–816
  30. Tong MJ , El-Farra NS , Reikes AR , Co RL . Clinical outcomes after transfusion-associated hepatitis C . N Engl J Med . 1995;332:1463–1466
  31. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C (results of a large, prospective cohort study) . Hepatology . 1998;28:1687–1695
  32. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C . Hepatology . 1996;23:1334–1340
  33. Matsumara H , Moriyama K , Goto I , Okubo J , Arakawa T . Natural course of progression of fibrosis in Japanese patients with chronic liver disease type C—a study of 527 patients at one establishment . J Viral Hepat . 2000;7:268–275
  34. Takahashi M , Yamada G , Miyamoto R , Doi T , Endo H , Tsuji T . Natural course of chronic hepatitis C . Am J Gastroenterol . 1993;88:240–243
  35. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C (a retrospective follow-up study of 384 patients) . Gastroenterology . 1997;112:463–472
  36. Di Bisceglie AM . Hepatitis C and hepatocellular carcinoma . Hepatology . 1997;26(Suppl 1):34S–38S
  37. El-Serag HB . Hepatocellular carcinoma and hepatitis C in the United States . Hepatology . 2002;36(Suppl 1):S74–S83
  38. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al  Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma (analysis by detection of antibody to hepatitis C virus) . Hepatology . 1990;12:671–675
  39. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis (a prospective observation of 2215 patients) . J Hepatol . 1998;28:930–938
  40. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C (a randomised trial) . Lancet . 2001;358:958–965
  41. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection . N Engl J Med . 2002;347:975–982
  42. Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C (a randomized study of treatment duration and ribavirin dose) . Ann Intern Med . 2004;140:346–355
  43. Shindo M , Di Bisceglie AM , Hoofnagle JH . Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon . Hepatology . 1992;15:1013–1016
  44. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C . Hepatology . 2000;32:1131–1137
  45. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy . Ann Intern Med . 2000;132:517–524
  46. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C (a dynamic view) . Gastroenterology . 1999;116:378–386
  47. Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C (a meta-analysis of individual patient data) . Hepatology . 2004;39:333–342
  48. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma (national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan) . Ann Intern Med . 1999;131:174–181
  49. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis . Lancet . 1995;346:1051–1055
  50. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients . Gastroenterology . 2002;123:483–491
  51. NHS Center for Reviews and Dissemination . Undertaking systematic reviews of research on effectiveness (CRD guidelines for those carrying out or commissioning reviews) . York: University of York; 1996; CRD report #4
  52. Alter HJ , Seeff LB . Recovery, persistence, and sequelae in hepatitis C virus infection (a perspective on long-term outcome) . Semin Liver Dis . 2000;20:17–35
  53. Hoofnagle J . Hepatitis C (the clinical spectrum of disease) . Hepatology . 1997;26(Suppl 1):15S–20S
  54. Seeff LB . Natural history of chronic hepatitis C . Hepatology . 2002;36(Suppl 1):S35–S46
  55. Vogt M, Lang T, Frosner G, Klinger C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening . N Engl J Med . 1999;341:866–870
  56. Kenny-Walsh E  Irish Hepatology Research Group . Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin . N Engl J Med . 1999;340:1228–1233
  57. Wiese M , Berr F , Lafrenz M , Porast H , Oesen U  East German Hepatitis C Study Group . Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany (a 20-year multicenter study) . Hepatology . 2000;32:91–96
  58. Bjøro K , Frøland SS , Yun Z , Samdal HH , Haaland T . Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin . N Engl J Med . 1994;331:1607–1611
  59. Poynard T , Bedossa P , Opolon P  OBSVIRC, METAVIR, CLINIVIR, DOSVIRC Groups . Natural history of liver fibrosis progression in patients with chronic hepatitis C . Lancet . 1997;349:825–832
  60. Marcellin P , Asselah T , Boyer N . Fibrosis and disease progression in hepatitis C . Hepatology . 2002;36(Suppl 1):S47–S56
  61. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C . Gastroenterology . 2003;124:97–104
  62. Lagging LM, Westin J, Svensson E, Aires N, Dhillon AP, Lindh M, et al. Progression of fibrosis in untreated patients with hepatitis C virus infection . Liver . 2002;22:136–144
  63. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, et al. Volunteer blood donors with antibody to hepatitis C virus (clinical, biochemical, virologic, and histologic features) . Ann Intern Med . 1995;123:330–337
  64. Alric L, Fort M, Izopet J, Vinel J-P, Charlet J-P, Selves J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection . Gastroenterology . 1997;113:1675–1681
  65. Kuzushita N, Hayashi N, Moribe T, Katayama K, Kanto T, Nakatani S, et al. Influence of HLA haplotypes on the clinical course of individuals infected with hepatitis C virus . Hepatology . 1998;27:240–244
  66. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection (host, viral, and environmental factors) . JAMA . 2000;284:450–456
  67. Adinolfi LE , Gambardella M , Andreana A , Tripodi MF , Utili R , Ruggiero G . Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity . Hepatology . 2001;33:1358–1364
  68. Hourigan LF, MacDonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis . Hepatology . 1999;29:1215–1219
  69. Alberti A , Benvegnù L . Management of hepatitis C . J Hepatol . 2003;38(Suppl 1):S104–S118
  70. Poynard T , Ratziu V , Charlotte F , Goodman Z , McHutchison J , Albrecht J . Rates and risk factors for liver fibrosis in hepatitis C virus infected patients . J Hepatol . 2001;34:730–739
  71. Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients . Gut . 2003;52:1035–1040
  72. Negro F . Hepatitis C virus and liver steatosis (when fat is not beautiful) . J Hepatol . 2004;40:533–535
  73. Martin P , Di Bisceglie AM , Kassianides C , Lisker-Melman M , Hoofnagle JH . Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection . Gastroenterology . 1989;97:1559–1561
  74. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients . Hepatology . 1999;30:1054–1058
  75. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection (a meta-analysis) . Clin Infect Dis . 2001;33:562–569
  76. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis . J Hepatol . 1997;26:1–5
  77. Howell C , Jeffers L , Hoofnagle JH . Hepatitis C in African-Americans (summary of a workshop) . Gastroenterology . 2000;119:1385–1396
  78. Crosse K, Umeadi OG, Anania FA, Laurin J, Papadimitriou J, Drachenberg C, et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C . Clin Gastroenterol Hepatol . 2004;2:463–468
  79. Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans . Clin Gastroenterol Hepatol . 2004;2:469–473
  80. Benvegnu L , Gios M , Boccato S , Alberti A . Natural history of compensated viral cirrhosis (a prospective study on the incidence and hierarchy of major complications) . Gut . 2004;53:744–749
  81. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand A-M, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis . Hepatology . 1998;27:1435–1440
  82. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis (a prospective study) . Hepatology . 1997;25:754–758
  83. El-Serag HB , Mason AC . Rising incidence of hepatocellular carcinoma in the United States . N Engl J Med . 1999;340:745–750
  84. Dienstag JL . The role of liver biopsy in chronic hepatitis C . Hepatology . 2002;36(Suppl 1):S152–S160
  85. Strader DB . Understudied populations with hepatitis C . Hepatology . 2002;36(Suppl 1):S226–S236
  86. Edlin BR . Prevention and treatment of hepatitis C in injection drug users . Hepatology . 2002;36(Suppl 1):S210–S219
  87. Peters MG , Terrault NA . Alcohol use and hepatitis C . Hepatology . 2002;36(Suppl 1):S220–S225
  88. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine aminotransferase activity . Hepatology . 1998;27:868–872
  89. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels . Gastroenterology . 2000;118:760–764
  90. Martinon-Peignoux M, Boyer N, Cazals-Hatem D, Pham B-N, Gervais A, Le Breton V, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA . Hepatology . 2001;34:1000–1005
  91. Wali M, Lewis S, Hubscher S, Harrison R, Ahmed M, Elias E, et al. Histologic progression during short-term follow-up of patients with chronic hepatitis C virus infection . J Viral Hepat . 1999;6:445–452
  92. Bacon BR . Treatment of patients with hepatitis C and normal serum aminotransferase levels . Hepatology . 2002;36(Suppl 1):S179–S184
  93. Ahmed A , Keeffe EB . Chronic hepatitis C with normal aminotransferase levels . Gastroenterology . 2004;126:1409–1415
  94. Pawlotsky J-M . Use and interpretation of virological tests for hepatitis C . Hepatology . 2002;36(Suppl 1):S65–S73
  95. Pawlotsky J-M . Molecular diagnosis of viral hepatitis . Gastroenterology . 2003;122:1554–1568
  96. Davis GL , Wong JB , McHutchison JG , Manns MP , Harvey J , Albrecht J . Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C . Hepatology . 2003;38:645–652
  97. Bukh J , Miller RH , Purcell RH . Genetic heterogeneity of hepatitis C virus (quasispecies and genotypes) . Semin Liver Dis . 1995;15:41–63
  98. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes . Hepatology . 1994;19:1321–1324
  99. Simmonds P . Variability of hepatitis C virus . Hepatology . 1995;21:570–583
  100. Hoofnagle JH . Course and outcome of hepatitis C . Hepatology . 2002;36(Suppl 1):S21–S29
  101. Zeuzem S . Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C (who responds less well?) . Ann Intern Med . 2004;140:346–355
  102. el-Zayadi A, Selim O, Haddad S, Simmonds P, Hamdy H, Badran HM, et al. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients . Ital J Gastroenterol Hepatol . 1999;31:472–475
  103. Koshy A , Marcellin P , Martinot M , Madda JP . Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis . Liver . 2000;20:335–339
  104. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histologic grading and staging of chronic hepatitis . J Hepatol . 1995;22:696–699
  105. Bedossa P , Poynard T  French METAVIR Cooperative Study Group . An algorithm for grading activity in chronic hepatitis C . Hepatology . 1994;24:289–293
  106. Poynard T , Ratziu V , Benmanov Y , Di Martino V , Bedossa P , Opolon P . Fibrosis in patients with chronic hepatitis C (detection and significance) . Semin Liver Dis . 2000;20:47–55
  107. Wong JB , Koff RS . Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis . Ann Intern Med . 2000;133:665–675
  108. Cadranel JF , Rufat P , Degos F  The Group of Epidemiology of the French Association for the Study of the Liver (AFEF) . Practices of liver biopsy in France (results of a prospective nationwide survey) . Hepatology . 2000;32:477–481
  109. Bressler BL , Guindi M , Tomlinson G , Heathcote J . High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C . Hepatology . 2003;38:639–644
  110. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients . J Hepatol . 2004;40:484–490
  111. Westin J , Nordlinder H , Lagging M , Norkrans G , Wejstal R . Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients . J Hepatol . 2002;37:837–842
  112. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HCJ, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa (a multicenter randomized, controlled trial) . N Engl J Med . 1989;321:1501–1506
  113. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C (a randomized, double-blind, placebo-controlled trial) . N Engl J Med . 1989;321:1506–1510
  114. Niederau C , Heintges T , Haussinger D . Treatment of chronic hepatitis C with a-interferon (an analysis of the literature) . Hepatogastroenterology . 1996;43:1544–1556
  115. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C (effects of dose and duration) . Hepatology . 1996;24:778–789
  116. Carithers RLJ , Emerson SS . Therapy of hepatitis C (meta-analysis of interferon alfa-2b trials) . Hepatology . 1997;26(Suppl 1):83S–88S
  117. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers . J Hepatol . 1997;26:961–966
  118. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon alpha therapy . Ann Intern Med . 1997;127:875–881
  119. Lau DT , Kleiner DE , Ghany MG , Park Y , Schmid M , Hoofnagle JH . 10-year follow-up after interferon-alpha therapy for chronic hepatitis C . Hepatology . 1998;28:1121–1127
  120. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C (results of a placebo-controlled study) . J Hepatol . 1996;25:591–598
  121. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C (a randomized, double-blind, placebo-controlled trial) . Ann Intern Med . 1995;123:897–903
  122. Bodenheimer HC , Lindsay KL , Davis GL , Lewis JH , Thung SN , Seeff LB . Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C (a multicenter trial) . Hepatology . 1997;26:473–477
  123. Schvarcz R , Yun ZB , Sonnerborg A , Weiland O . Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone . J Med Virol . 1995;46:43–47
  124. Reichard O , Norkrans G , Fryden A , Braconier J-H , Sonnerborg A , Weiland O  Swedish Study Group . Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C . Lancet . 1998;351:83–87
  125. Lai M-Y, Kao J-H, Yang P-M, Wang J-T, Chen P-J, Chan K-W, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C . Gastroenterology . 1996;111:1307–1312
  126. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C . N Engl J Med . 1998;339:1485–1492
  127. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus . Lancet . 1998;352:1426–1432
  128. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Lellicelli A, Grisorio B, et al. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C (an Italian multicenter experience) . J Hepatol . 2000;33:448–455
  129. Pol S, Nalpas B, Bourliere M, Couzigou P, Tran A, Abergel A, et al. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C . Hepatology . 2000;31:1338–1344
  130. Kjaergard LL , Krogsgaard K , Gluud C . Interferon alfa with or without ribavirin for chronic hepatitis C (systematic review of randomised trials) . BMJ . 2001;323:1151–1155
  131. Cramp ME , Rossol S , Chokshi S , Carucci P , Williams R , Naumov NV . Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C . Gastroenterology . 2000;118:346–355
  132. Fang SH , Hwang LH , Chen DS , Chiang BL . Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 levels . J Hepatol . 2000;33:791–798
  133. Reichard O , Schvarc R , Weiland O . Therapy of hepatitis C (alpha interferon and ribavirin) . Hepatology . 1997;26(Suppl 1):108S–111S
  134. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, et al. Ribavirin inhibits viral-induced macrophage production of tumor necrosis factor, interleukin-1, and procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response . J Immunol . 1998;160:3487–3493
  135. Hong Z . The role of ribavirin-induced mutagenesis in HCV therapy (a concept or a fact?) . Hepatology . 2003;38:807–810
  136. Lau JY , Tam RC , Liang TJ , Hong Z . Mechanism of action of ribavirin in the combination treatment of chronic HCV infection . Hepatology . 2002;35:1002–1009
  137. Crotty S , Cameron CE , Andino R . RNA virus error catastrophe (direct molecular test by using ribavirin) . Proc Natl Acad Sci U S A . 2001;98:6895–6900
  138. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JYN, Hong Z, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen . Nat Med . 2000;6:1375–1379
  139. Contreras AM , Hiasa Y , He W , Terella A , Schmidt EV , Chung RT . Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system . J Virol . 2002;76:8505–8517
  140. Pawlotsky J-M, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C . Gastroenterology . 2004;126:703–714
  141. Dixit NM , Layden-Almer JE , Layden TJ , Perelson AS . Modelling how ribavirin improves interferon response rates in hepatitis C virus infection . Nature . 2004;432:922–924
  142. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai M-Y, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C . N Engl J Med . 2000;343:1666–1672
  143. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis . N Engl J Med . 2000;343:1673–1680
  144. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C . Hepatology . 2001;33:433–438
  145. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C . Hepatology . 2001;34:395–403
  146. Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Marcellin P, et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C (a multicenter, randomized controlled trial) . Am J Gastroenterol . 2004;99:1298–1305
  147. FDA advisory documents for PEG-IFN alfa-2b and PEG-IFN alfa-2a . 2005; Available at: http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3819t1.htm and http://www.fda.gov/chrms/dockets/ac/02/transcripts/3909t1.htm. Accessed August 16, 2005.
  148. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay K, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C . Gastroenterology . 2002;123:1061–1069
  149. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3 . J Hepatol . 2004;40:993–999
  150. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 . N Engl J Med . 2005;352:2609–2617
  151. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy . Science . 1998;282:103–107
  152. Zeuzem S , Schmidt JM , Lee JH , von Wagner M , Teuber G , Roth WK . Hepatitis C virus dynamics in vivo (effect of ribavirin and interferon alfa on viral turnover) . Hepatology . 1998;28:245–252
  153. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alfa-2a . Gastroenterology . 2001;120:1438–1447
  154. Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin . Hepatology . 2002;35:930–936
  155. Layden-Almer JE , Ribeiro RM , Wiley T , Perelson AS , Layden TJ . Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin . Hepatology . 2003;37:1343–1350
  156. Davis GL . Monitoring of viral levels during therapy of hepatitis C . Hepatology . 2002;36(Suppl 1):S145–S151
  157. Camma C , Giunta M , Linea C , Pagliaro L . The effect of interferon on the liver in chronic hepatitis C (a quantitative evaluation of histology by meta-analysis) . J Hepatol . 1997;26:1187–1199
  158. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C . Gastroenterology . 2002;122:1303–1313
  159. Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C . Hepatology . 1997;26:780–785
  160. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia . Gastroenterology . 1999;117:1164–1172
  161. Knodell R, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis . Hepatology . 1981;1:431–435
  162. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B . Gastroenterology . 1988;95:1318–1325
  163. McHutchison JG, Ware JEJ, Bayliss MS, Pianko S, Albrecht JK, Cort S, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity . Hepatology . 2001;34:140–147
  164. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HCJ, Perrillo RP, et al. Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile . Clin Ther . 1994;16:334–343
  165. Bonkovsky HL , Woolley M  The Consensus Interferon Study Group . Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy . Hepatology . 1999;29:264–270
  166. Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death . J Viral Hepat . 2004;11:148–156
  167. Younossi ZM , Singer ME , McHutchison JG , Shermock KM . Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C . Hepatology . 1999;30:1318–1324
  168. Salomon JA , Weinstein MC , Hammitt JK , Goldie SJ . Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population . JAMA . 2003;290:228–237
  169. Bennett WG , Inoue Y , Beck JR , Wong JB , Pauker SG , Davis GL . Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C . Ann Intern Med . 1997;127:855–865
  170. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis . J Hepatol . 1996;24:141–147
  171. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis C (a long-term observational study of 1,643 patients using statistical bias correction with proportional hazard analysis) . Hepatology . 1999;29:1124–1130
  172. Camma C , Giunta M , Andreone P , Craxi A . Interferon and prevention of hepatocellular carcinoma in viral cirrhosis (an evidence-based approach) . J Hepatol . 2001;34:593–602
  173. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, et al. Treatment of chronic hepatitis C (a systematic review) . Hepatology . 2002;36(Suppl 1):S135–S144
  174. Bernardinello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, Benvegnù L, et al. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C . Hepatogastroenterology . 1999;46:3216–3222
  175. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C . J Hepatol . 1997;27:201–205
  176. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment . Gastroenterology . 2004;126:1015–1023
  177. Fried MW . Side effects of therapy of hepatitis C and their management . Hepatology . 2002;36(Suppl 1):S237–S244
  178. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C . N Engl J Med . 1998;339:1493–1499
  179. Russo MW , Fried MW . Side effects of therapy for chronic hepatitis C . Gastroenterology . 2003;124:1711–1719
  180. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C . Hepatology . 2002;36:1273–1279
  181. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection (role of membrane oxidative damage) . Hepatology . 2000;31:997–1004
  182. Chang CH , Chen KY , Lai MY , Chan KA . Meta-analysis (ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C) . Aliment Pharmacol Ther . 2002;16:1623–1632
  183. Dieterich DT, Wasserman R, Bräu N, Hassanein TI, Bibi EJ, Bowers PJ, et al. Once weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon α . Am J Gastroenterol . 2003;98:2491–2499
  184. Dieterich DT , Spivak JL . Hematologic disorders associated with hepatitis C virus infection and their management . Clin Infect Dis . 2003;37:533–541
  185. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients (a prospective, double-blind, randomiized controlled study) . Gastroenterology . 2004;126:1302–1311
  186. Wu JZ , Walker H , Lau JY , Hong Z . Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme (adenosine deaminase catalyzes two consecutive deamination reactions) . Antimicrob Agents Chemother . 2003;47:426–431
  187. Watson J . Prospects for hepatitis C virus therapeutics (levovorin and viramidine as improved derivatives of ribavirin) . Curr Opin Invest Drugs . 2002;3:680–683
  188. Gish R , Arora S , Nelson D , Fernandez H , Lamon K . Safety and efficacy of viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naïve patients . (abstr) J Hepatol . 2004;40(Suppl 1):141–142
  189. Fontana RJ , Everson GT , Tuteja S , Vargas HE , Shiffman ML . Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis . Clin Gastroenterol Hepatol . 2004;2:183–197
  190. Wright TL . Treatment of patients with hepatitis C and cirrhosis . Hepatology . 2002;36(Suppl 1):S185–S194
  191. Crippin JS , McCashland T , Terrault N , Sheiner P , Charlton MR . A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation . Liver Transpl . 2002;8:350–355
  192. Everson G . Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (low-accelerating-dose regimen) . (abstr) Hepatology . 2002;36:297A
  193. Everson GT . Treatment of patients with hepatitis C virus on the waiting list . Liver Transpl . 2003;9:S90–S94
  194. Thomas RM , Brems JJ , Guzman-Hartman G , Yong S , Cavaliere P , Van Thiel DH . Infection with chronic hepatitis C virus and liver transplantation (a role for interferon therapy before transplantation) . Liver Transpl . 2003;9:905–915
  195. Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation . J Hepatol . 2003;39:389–396
  196. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy . Hepatology . 2005;42:255–262
  197. Di Bisceglie AM , Hoofnagle JH . Optimal therapy of hepatitis C . Hepatology . 2002;36(Suppl 1):S121–S127
  198. Falck-Ytter Y , Kale H , Mullen KD , Sarbah SA , Sorescu L , McCullough AJ . Surprisingly small effect of antiviral treatment in patients with hepatitis C . Ann Intern Med . 2002;136:288–292
  199. Shehab TM , Fontana RJ , Oberhelman K , Marrero JA , Su GL , Lok ASF . Effectiveness of interferon α-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice . Clin Gastroenterol Hepatol . 2004;2:425–431
  200. McHutchison J, Davis GL, Esteban-Mur R, Poynard T, Ling M-H, Garaud J-J, et al. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon alfa-2b alone or in combination with ribavirin . (abstr) Hepatology . 2001;34:244A
  201. Perrillo RP . The role of liver biopsy in hepatitis C . Hepatology . 1997;26(Suppl 1):57S–61S
  202. Davis GL, Lindsay K, Albrecht J, Bodenheimer HC, Balart LA, Perrillo RP, et al. Clinical predictors of response to recombinant alpha interferon-α treatment in patients with chronic non-A, non-B hepatitis (hepatitis C) . J Viral Hepat . 1994;1:55–63
  203. Verbaan HP , Widell HE , Bondeson TL , Lindgren SC . High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin . Eur J Gastroenterol Hepatol . 2002;14:627–633
  204. Di Bisceglie AM , Thompson J , Smith-Wilkaitis N , Brunt EM , Bacon BR . Combination of interferon and ribavirin in chronic hepatitis C (re-treatment of nonresponders to interferon) . Hepatology . 2001;33:704–707
  205. Gordon SC , Fang JW , Silverman AL , McHutchison JG , Albrecht J . The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C . Hepatology . 2000;32:400–404
  206. Lee SS , Sherman M . Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values . J Viral Hepat . 2001;8:202–205
  207. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels . Gastroenterology . 2004;127:1724–1732
  208. Jacobson IM, Ahmed F, Russo MW, Lebovics E, Dieterich DT, Esposito SP, et al. Interferon alfa-2b and ribavirin for patients with chronic hepatitis C and normal ALT . Am J Gastroenterol . 2004;99:1700–1705
  209. Wong JB , Koff RS , Tine F , Pauker SG . Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B . Ann Intern Med . 1995;122:664–675
  210. Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis (analysis of individual patient data of six controlled trials) . Gastroenterology . 1999;117:408–413
  211. Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C . J Hepatol . 2003;39:106–111
  212. Shiffman ML . Retreatment of patients with chronic hepatitis C . Hepatology . 2002;36(Suppl 1):S128–S134
  213. Camma C, Giunta M, Chemello L, Alberti A, Toyoda H, Trepo C, et al. Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data . Hepatology . 1999;30:801–807
  214. Myers RP , Poynard T . Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C . Cochrane Database Syst Rev . 2002; CD003617
  215. Saracco G, Olivero A, Ciancio A, Carenzi S, Smedile A, Cariti G, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy . Hepatology . 2002;36:959–966
  216. Min AD, Jones JL, Esposito S, Lebovics E, Jacobson IM, Klion FM, et al. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone . Am J Gastroenterol . 2001;96:1143–1149
  217. Marco VD, Almasio P, Vaccaro A, Ferraro D, Parisi P, Cataldo M, et al. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months . J Hepatol . 2000;33:456–462
  218. Enriquez J, Gallego A, Torras X, Perez-Olmeda T, Diago M, Soriano V, et al. Retreatment for 24 vs. 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone . J Viral Hepat . 2000;7:403–408
  219. Barbaro G, Di Lorenzo G, Belloni G, Ferrari L, Paiano A, Del Poggio P, et al. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy (a randomized trial) . Am J Med . 1999;107:112–118
  220. Shiffman ML , Hofmann CM , Sterling RK , Luketic VA , Contos MJ , Sanyal AJ . A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response . J Infect Dis . 2001;184:405–409
  221. Jacobson IM, Ahmed F, Russo MW, Brown RSJ, Lebovics E, Min A, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C. A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: final results (abstr) . Gastroenterology . 2003;124(Suppl 1):A714
  222. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon . JAMA . 2001;285:193–199
  223. Cheng SJ , Bonis PA , Lau J , Pham NQ , Wong JB . Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy (a meta-analysis of controlled and uncontrolled trials) . Hepatology . 2001;33:231–240
  224. Shiffman ML, Hofmann CM, Gabbay J, Luketic VA, Sterling RK, Sanyal AJ, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy (effects of higher doses of interferon and ribavirin combination therapy) . Am J Gastroenterol . 2000;95:2928–2935
  225. Camma C , Almasio P , Craxi A . Interferon as treatment for acute hepatitis C. A meta-analysis . Dig Dis Sci . 1996;41:1248–1255
  226. Quin JW . Interferon therapy for acute hepatitis C viral infection—a review by meta-analysis . Aust N Z J Med . 1997;27:611–617
  227. Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, et al. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C (a pilot study) . Dig Dis Sci . 1996;41(Suppl):81S–85S
  228. Fabris P , Tositti G , Giordani MT , Infantolino D , de Lalla F . Three times weekly versus daily dose alpha-interferon treatment in patients with acute hepatitis C . Am J Gastroenterol . 2002;97:492–493
  229. Calleri G, Colombatto P, Gozzelino M, Chieppa F, Romano P, Delmastro B, et al. Natural beta interferon in acute type-C hepatitis patients (a randomized controlled trial) . Ital J Gastroenterol Hepatol . 1998;30:181–184
  230. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b . N Engl J Med . 2001;345:1452–1457
  231. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C (high rate of both spontaneous and treatment-induced viral clearance) . Gastroenterology . 2003;125:80–88
  232. Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, et al. Short-term inteferon-alfa therapy for acute hepatitis C (a randomized controlled trial) . Hepatology . 2004;39:1213–1219
  233. Alberti A , Boccato S , Vario A , Benvegnù L . Therapy of acute hepatitis C . Hepatology . 2002;36(Suppl 1):S195–S200
  234. Wedemeyer H , Jackel E , Wiegand J , Cornberg M , Manns MP . Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C . Hepatology . 2004;39:1201–1203
  235. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, et al. Pegylated interferon α therapy in acute hepatitis C (relation to hepatitis C virus-specific T cell response kinetics) . Hepatology . 2004;39:1721–1731
  236. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment . Am J Epidemiol . 2002;155:645–653
  237. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? . N Engl J Med . 2001;345:211–214
  238. Neri S, Bruno CM, Abate G, Ierna D, Mauceri B, Cilio D, et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b . Clin Ther . 2002;24:1627–1635
  239. Sylvestre DL . Treating hepatitis C in methadone maintenance patients (an interim analysis) . Drug Alcohol Depend . 2002;67:117–123
  240. Backmund M , Meyer K , von Zielonka M , Eichenlaub D . Treatment of hepatitis C infection in injection drug users . Hepatology . 2001;34:188–193
  241. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, et al. Treatment of chronic hepatitis C in injecting drug users (5 years’ follow-up) . Eur Addict Res . 2002;8:45–49
  242. Brillanti S , Masci C , Siringo S , Di Febo G , Miglioli M , Barbara L . Serological and histological aspects of hepatitis C virus infection in alcoholic patients . J Hepatol . 1991;13:347–350
  243. Wiley TE , McCarthy M , Breidi L , Layden TJ . Impact of alcohol on the histologica and clinical progression of hepatitis C infection . Hepatology . 1998;28:805–809
  244. Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Croce LS, Mazzoran L, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population (report from the Dionysos study) . Gut . 1999;44:874–880
  245. Gao B , Hong F , Radaeva S . Host factors and failure of interferon-α treatment in hepatitis C virus . Hepatology . 2004;39:880–890
  246. Ohnishi K, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers (comparison with chronic hepatitis C in infrequent drinkers) . Am J Gastroenterol . 1996;91:1374–1379
  247. Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers . Scand J Gastroenterol . 1994;29:1039–1043
  248. Tabone M, Sidoli L, Laudi C, Pellegrino S, Rocca G, Della Monica P, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy . J Viral Hepat . 2002;9:288–294
  249. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C . Hepatology . 1999;30:787–793
  250. Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians . J Viral Hepat . 2001;8:264–269
  251. De Maria N , Colantoni A , Idilman R , Friedlander L , Harig J , Van Thiel DH . Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C . Hepatogastroenterology . 2002;49:788–792
  252. Theodore D, Shiffman ML, Sterling RK, Bruno CJ, Weinstein J, Crippin JS, et al. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C . Dig Dis Sci . 2003;48:140–145
  253. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C . Gastroenterology . 2000;119:1317–1323
  254. Muir AJ , Bornstein JD , Killenberg PG  Atlantic Coast Hepatitis Treatment Group . Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites . N Engl J Med . 2004;350:2265–2271
  255. Jeffers LJ , Cassidy W , Howell CD , Hu S , Reddy KR . Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 . Hepatology . 2004;39:1702–1708
  256. Dienstag JL . Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features . Gastroenterology . 1983;85:439–462
  257. Brettler DB , Alter HJ , Dienstag JL , Forsberg AD , Levine PH . Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients . Blood . 1990;76:254–256
  258. Eyster ME , Alter HJ , Aledort LM , Quan S , Hatzakis A , Goedert JJ . Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) . Ann Intern Med . 1991;115:764–768
  259. Fried MW, Peter J, Hoots K, Gaglio PJ, Talbut D, Davis PC, et al. Hepatitis C in adults and adolescents with hemophilia (a randomized, controlled trial of interferon alfa-2b and ribavirin) . Hepatology . 2002;36:967–972
  260. Schulman S , Grillner L . Antibodies against hepatitis C in a population of Swedish hemophiliacs and heterosexual partners . Scand J Infect Dis . 1990;22:393–397
  261. Stevens CE , Silbert JA , Miller DR , Dienstag JL , Purcell RH , Szmuness W . Serologic evidence of hepatitis A and B virus infections in thalassemia patients (a retrospective study) . Transfusion . 1978;18:356–360
  262. Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, et al. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy (a long term follow-up study in hepatitis C-infected patients with beta thalassemia major) . Am J Gastroenterol . 2002;97:982–987
  263. Donohue SM, Wonke B, Hoffbrand AV, Reittie J, Ganeshaguru K, Scheuer PJ, et al. Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major . Br J Haematol . 1993;83:491–497
  264. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, et al  Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C . J Pediatr . 1994;125:123–128
  265. Spiliopoulou I , Repanti M , Katinakis S , Karana-Ginopoulou A , Papanastasiou DA . Response to interferon alfa-2b therapy in mutitransfused children with beta-thalassemia and chronic hepatitis C . Eur J Clin Microbiol Infect Dis . 1999;18:709–715
  266. Di Marco V, Lo Iacono O, Almasio P, Ciaccio C, Capra M, Rizzo M, et al. Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C . Blood . 1997;90:2207–2212
  267. Telfer PT, Garson JA, Whitby K, Grant PR, Yardumian A, Hoffbrand AV, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients . Br J Haematol . 1997;98:850–855
  268. Li CK , Chan PK , Ling SC , Ha SY . Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major . Br J Haematol . 2002;117:755–758
  269. Hanley JP, Jarvis LM, Andrew J, Dennis R, Hayes PC, Piris J, et al. Interferon treatment for chronic hepatitis C infection in hemophiliacs—influence of virus load, genotype, and liver pathology on response . Blood . 1996;87:1704–1709
  270. Rumi MG, Santagostino E, Morfini M, Gringeri A, Tagariello G, Chistolini A, et al. A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C . Blood . 1997;89:3529–3533
  271. Laursen AL, Scheibel E, Ingerslev J, Clausen NC, Wantzin P, Ostergaard L, et al. Alpha interferon therapy in Danish haemophiliac patients with chronic hepatitis C (results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon-alpha-2b treatment) . Haemophilia . 1998;4:25–32
  272. Franchini M, Tagliaferri A, Rossetti G, Capra F, Veneri D, de Maria E, et al. Interferon and ribavirin in HIV-negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment . Haemophilia . 2002;8:794–797
  273. Makris M , Preston FE , Triger DR , Underwood JC , Westlake L , Adelman MI . A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs . Blood . 1991;78:1672–1677
  274. Makris M, Baglin T, Dusheiko G, Giangrande PL, Lee CA, Ludlam CA, et al. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia . Haemophilia . 2001;7:339–345
  275. Ko JS , Choe YH , Kim EJ , Lee EH , Jang JJ , Seo JK . Interferon-alpha treatment of chronic hepatitis C in children with hemophilia . J Pediatr Gastroenterol Nutr . 2001;32:41–44
  276. Shields PL, Mutimer DJ, Muir D, Skidmore S, Britnell T, Roberts A, et al. Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders . Br J Haematol . 2000;108:254–258
  277. Sauleda S , Esteban JI , Altisent C , Puig L , Esteban R , Guardia J . Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C . Thromb Haemost . 2000;83:807–810
  278. Schwimmer JB , Balistreri WF . Transmission, natural history, and treatment of hepatitis C virus infection in the pediatric population . Semin Liver Dis . 2000;20:37–46
  279. Jonas MM . Children with hepatitis C . Hepatology . 2002;36(Suppl 1):S173–S178
  280. Jonas MM . Treatment of chronic hepatitis C in pediatric patients . Clin Liver Dis . 1999;3:855–867
  281. Jacobson KR , Murray K , Zellos A , Schwarz KB . An analysis of published trials of interferon monotherapy in children with chronic hepatitis C . J Pediatr Gastroenterol Nutr . 2002;34:52–58
  282. Gentil MA, Rocha JL, Rodriguez-Algarra G, Pereira P, Lopez R, Bernal G, et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus . Nephrol Dial Transplant . 1999;14:2455–2460
  283. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome . Hepatology . 1999;29:257–263
  284. Rostaing L , Modesto A , Baron E , Cisterne JM , Chabannier MH , Durand D . Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C . Nephron . 1996;74:512–516
  285. Chan TM , Lok AS , Cheng IK , Ng IO . Chronic hepatitis C after renal transplantation. Treatment with alpha-interferon . Transplantation . 1993;56:1095–1098
  286. Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function (clinical implications) . J Am Soc Nephrol . 1998;9:2344–2348
  287. Russo MW , Goldsweig CD , Jacobson IM , Brown RS . Interferon monotherapy for dialysis patients with chronic hepatitis C (an analysis of the literature on efficacy and safety) . Am J Gastroenterol . 2003;98:1610–1615
  288. Fabrizi F , Poordad FF , Martin P . Hepatitis C infection and the patient with end-stage renal disease . Hepatology . 2002;36:3–10
  289. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection (a multicentre, prospective study) . Nephrol Dial Transplant . 2001;16:1017–1023
  290. Fernandez JL , Rendo P , del Pino N , Viola L  Nephrologists’ Group for the Study of HCV Infection . A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels . J Viral Hepat . 1997;4:113–119
  291. Izopet J, Rostaing L, Moussion F, Alric L, Dubois M, That HT, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy . J Infect Dis . 1997;176:1614–1617
  292. Campistol JM, Esforzado N, Martinez J, Rosello L, Veciana L, Modol J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment . Nephrol Dial Transplant . 1999;14:2704–2709
  293. Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Perez JL, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis (results after transplantation) . Am J Gastroenterol . 2001;96:1170–1177
  294. Gursoy M , Gur G , Arslan H , Ozdemir N , Boyacioglu S . Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment . J Viral Hepat . 2001;8:70–77
  295. Hanrotel C, Toupance O, Lavaud S, Thiefin G, Brodard V, Ingrand D, et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C . Nephron . 2001;88:120–126
  296. Bruchfeld A , Stahle L , Andersson J , Schvarcz R . Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection—a pilot study . J Viral Hepat . 2001;8:287–292
  297. Dienstag JL , Bhan AK , Alter HJ , Feinstone SM , Purcell RH . Circulating immune complexes in non-A, non-B hepatitis (possible masking of viral antigen) . Lancet . 1979;1:1265–1267
  298. Adinolfi LE , Utili R , Zampino R , Ragone E , Mormone G , Ruggiero G . Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia . Eur J Gastroenterol Hepatol . 1997;9:1067–1072
  299. Polzien F , Schott P , Mihm S , Ramadori G , Hartmann H . Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia . J Hepatol . 1997;27:63–71
  300. Cresta P, Musset L, Cacoub P, Frangeul L, Vitour D, Poynard T, et al. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus . Gut . 1999;45:122–128
  301. Mazzaro C, Panarello G, Carniello S, Faelli A, Mazzi G, Crovatto M, et al. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis . Dig Liver Dis . 2000;32:708–715
  302. Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha . J Rheumatol . 2000;27:2172–2178
  303. Naarendorp M , Kallemuchikkal U , Nuovo GJ , Gorevic PD . Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection . J Rheumatol . 2001;28:2466–2473
  304. Alric L, Plaisier E, Thebault S, Peron JM, Rostaing L, Pourrat J, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN . Am J Kidney Dis . 2004;43:617–623
  305. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection . N Engl J Med . 1993;328:465–470
  306. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus . N Engl J Med . 1994;330:751–756
  307. Bonomo L , Casato M , Afeltra A , Caccavo D . Treatment of idiopathic mixed cryoglobulinemia with alpha interferon . Am J Med . 1987;83:726–730
  308. Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas . Ann Intern Med . 2002;137:571–580
  309. Mazzaro C, Franzin F, Tulissi P, Pussini E, Crovatto M, Carniello GS, et al. Regression of monoclonal B-cell expansion in patients affected by mnixed cryoglobulinemia responsive to alpha-interferon therapy . Cancer . 1996;77:2604–2613
  310. Thomas DL . Hepatitis C and human immunodeficiency virus infection . Hepatology . 2002;36(Suppl 1):S201–S209
  311. Sulkowski MS . Hepatitis C virus infection in HIV-infected patients . Current Hepat Rep . 2002;1:16–22
  312. Sulkowski MS , Moore RD , Mehta SH , Chaisson RE , Thomas DL . Hepatitis C and progression of HIV disease . JAMA . 2002;288:199–206
  313. Sulkowski MS , Thomas DL . Hepatitis C in the HIV-infected patient . Clin Liver Dis . 2003;7:179–194
  314. Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study) . AIDS . 2003;17:1803–1809
  315. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection . Clin Infect Dis . 2001;33:240–247
  316. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, McCabe RE, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy . Clin Infect Dis . 2003;36:363–367
  317. Lesens O , Deschenes M , Steben M , Belanger G , Tsoukas CM . Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection . J Infect Dis . 1999;179:1254–1258
  318. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, et al. Care of patients with chronic hepatitis C and HIV co-infection (recommendations from the HIV-HCV International Panel) . AIDS . 2002;16:813–828
  319. Perez-Olmeda M, Nunez M, Romero M, Gonzalez J, Castro A, Arribas JR, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients . AIDS . 2003;17:1023–1028
  320. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons . N Engl J Med . 2004;351:451–459
  321. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients (a randomized controlled trial) . JAMA . 2004;292:2839–2848
  322. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients . N Engl J Med . 2004;351:438–450
  323. Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients . AIDS . 2004;18:F27–F36
  324. Albert A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palú G, et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients . J Hepatol . 2005;42:615–624
  325. Di Martino V, Thevenot T, Boyer N, Cazals-Hatem D, Degott C, Valla D, et al. HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C . AIDS . 2002;16:441–445
  326. Lafeuillade A , Hittinger G , Chadapaud S . Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection . Lancet . 2001;357:280–281
  327. Kottilil S , Polis MA , Kivacs JA . HIV infection, hepatitis C infection, and HAART (hard clinical choices) . JAMA . 2004;292:243–250
  328. Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, et al. Immune recovery is associated with persistent rise in HCV RNA, infrequent liver test flares, and is not impaired by HCV in co-infected subjects . AIDS . 2002;16:1915–1923
  329. Wright TL . Liver transplantation for chronic hepatitis C viral infection . Gastroenterol Clin North Am . 1993;22:231–242
  330. Johnson MW, Washburn K, Freeman RB, FitzMaurice SE, Dienstag J, Basgoz N, et al. Hepatitis C viral infection in liver transplantation . Arch Surg . 1996;131:284–291
  331. Féray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotype of hepatitis C virus on the severity of recurrent liver disease after liver transplantation . Gastroenterology . 1995;108:1088–1096
  332. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation . N Engl J Med . 1996;334:815–820
  333. Féray C, Caccamo L, Alexander GJM, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C . Gastroenterology . 1999;117:619–625
  334. Charlton M . Hepatitis C infection in liver transplantation . Am J Transpl . 2001;1:197–203
  335. Berenguer M . Natural history of recurrent hepatitis C . Liver Transpl . 2002;8(Suppl 1):S14–S18
  336. Forman LM , Lewis JD , Berlin JA , Feldman HI , Lucey MR . The association between hepatitis C infection and survival after orthotopic liver transplantation . Gastroenterology . 2002;122:889–896
  337. McTaggart RA , Terrault NA , Vardanian AJ , Bostrom A , Feng S . Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation . Liver Transpl . 2004;10:975–985
  338. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following liver transplantation (relationship with rejection episodes) . Hepatology . 1999;29:250–256
  339. Fong TL , Valinluck B , Govindarajan S , Charboneau F , Adkins RH , Redeker AG . Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C . Gastroenterology . 1994;107:196–199
  340. Everson GT . Impact of immunosuppressive therapy on recurrence of hepatitis C . Liver Transpl . 2002;8(Suppl 1):S19–S27
  341. Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation (association with treatment of rejection) . J Hepatol . 1998;28:756–763
  342. Braun M , Vierling JM . The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host . Liver Transpl . 2003;9:S79–S89
  343. Doughty AL , Spenser JD , Cossart YE , McGaughan GW . Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels . Transpl Surg . 1998;4:15–21
  344. Cotler SJ, Taylor SL, Gretch DR, Bronner MP, Rozk R, Perkins JD, et al. Hyperbilirubinemia and cholestatic liver injury in hepatitis C-infected liver transplant recipients . Am J Gastroenterol . 2000;95:753–759
  345. Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, et al. Interferon-α therapy for hepatitis C infection after liver transplantation . Hepatology . 1994;20:773–779
  346. Gane EJ, Lo S-K, Riordan SM, Portmann BC, Lau JYN, Naoumov NV, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation . Hepatology . 1998;27:1403–1407
  347. Sheiner PA . Hepatitis C after liver transplantation . Semin Liver Dis . 2000;20:201–209
  348. Gane E . Treatment of recurrent hepatitis C . Liver Transpl . 2002;8(Suppl 1):S28–S37
  349. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation (a randomized study) . Gastroenterology . 2003;124:642–650
  350. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation . Hepatology . 1997;26:500–504
  351. Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C (results of an Italian multicenter randomized study) . Am J Gastroenterol . 2002;97:1204–1210
  352. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon (a multicenter, prospective, randomized, controlled trial) . Hepatology . 2000;32:135–138
  353. Mangia A, Minerva N, Annese M, Leandro G, Villani MR, Santoro R, et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C . Hepatology . 2001;33:989–993
  354. Brillanti S , Foli M , Di Tomaso M , Gramantieri L , Masci C , Bolondi L . Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders . Ital J Gastroenterol Hepatol . 1999;31:130–134
  355. Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, et al. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C . Hepatology . 2000;32:835–841
  356. Tabone M, Laudi C, Delmastro B, Biglino A, Andreoni M, Chieppa F, et al. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients . J Hepatol . 2001;35:517–521
  357. Younossi ZM, Mullen KD, Zakko W, Hodnick S, Brand E, Barnes DS, et al. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy . J Hepatol . 2001;34:128–233
  358. Helbling B, Stamenic I, Viani F, Gonvers JJ, Dufour JF, Reichen J, et al. Interferon and amantadine in naive chronic hepatitis C (a double-blind, randomized, placebo-controlled trial) . Hepatology . 2002;35:447–454
  359. Baisini O, Pigozzi MG, Benini F, Stellini R, Reggiani A, Quattrocchi D, et al. A randomised, open label, controlled trial on the effect of interferon plus amantadine compared with interferon alone for treatment of chronic hepatitis C . Hepatol Res . 2003;26:167–173
  360. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Pellicelli A, Grisorio B, et al. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha . Scand J Gastroenterol . 1999;34:928–933
  361. Bernardinello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, Benvegnu L, et al. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C . Hepatogastroenterology . 1999;46:3216–3222
  362. Shiratori Y, Nakata R, Shimizu N, Katada H, Hisamitsu S, Yasuda E, et al. High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load . Dig Dis Sci . 2000;45:2414–2421
  363. Suzuki F, Chayama K, Tsubota A, Akuta N, Someya T, Kobayashi M, et al. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen . J Gastroenterol . 2001;36:242–247
  364. Katayama K, Kasahara A, Sasaki Y, Kashiwagi T, Naito M, Masuzawa M, et al. Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance . J Viral Hepat . 2001;8:180–185
  365. Muir AJ , Sylvestre PB , Rockey DC . Interferon gamma-1b for the treatment of chronic HCV infection . (abstr) Gastroenterology . 2003;124:A718
  366. McHutchison JG, Giannelli G, Nyberg L, Blatt LM, Waite K, Mischkot P, et al. A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection . J Interferon Cytokine Res . 1999;19:1265–1270
  367. Nelson DR , Lauwers GY , Lau JY , Davis GL . Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C (a pilot trial of interferon nonresponders) . Gastroenterology . 2000;118:655–660
  368. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu LX, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammaatory effect . Hepatology . 2003;38:859–868
  369. Moscarella S, Buzzelli G, Romanelli RG, Monti M, Giannini C, Careccia G, et al. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C (preliminary results) . Liver . 1998;18:366–369
  370. Sherman KE, Sjogren M, Creager RL, Damiano MA, Freeman S, Lewey S, et al. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection (a randomized, placebo-controlled double-blind trial) . Hepatology . 1998;27:1128–1135
  371. Teran JC , Mullen KD , Hoofnagle JH , McCullough AJ . Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-α . Hepatology . 1994;19:849–856
  372. Alri L, Duffaut M, Selves J, Sandre K, Mularczyck M, Izopet J, et al. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response (results of a randomized trial) . J Hepatol . 2001;35:272–278
  373. Kalmowitz BD , Afdhal NH . Maintenance therapies for hepatitis C . Current Hepat Rep . 2004;3:23–29
  374. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial (pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders) . Control Clinical Trials . 2005;25:472–492
  375. Afdhal NH , Freilich B , Black M , Levine RW , Brass C . Comparison of therapy with PEG-Intron 0.5 mcg/kg versus colchicine 0.6 mg bid in 250 patients with cirrhosis and HCV (Interim data from COPILOT) . (abstr) Hepatology . 2002;36:312A
  376. Coon JT , Ernst E . Complementary and alternative therapies in the treatment of chronic hepatitis C (a systematic review) . J Hepatol . 2004;40:491–500
  377. Seeff LB , Lindsay KL , Bacon BR , Kresina TF , Hoofnagle JH . Complementary and alternative medicine in chronic liver disease . Hepatology . 2001;34:596–603
  378. Liu J , Manheimer E , Tsutani K , Gluud C . Medicinal herbs for hepatitis C virus infection (a Cochrane hepatobiliary systematic review of randomized trials) . Am J Gastroenterol . 2003;98:538–544

 This literature review and the recommendations therein were prepared for the American Gastroenterological Association Clinical Practice and Economics Committee. It was approved by the Committee on September 17, 2005, and by the AGA Governing Board on November 6, 2005.

PII: S0016-5085(05)02270-5

doi: 10.1053/j.gastro.2005.11.010

Gastroenterology
Volume 130, Issue 1 , Pages 231-264 , January 2006

Article Tools